Sanofi Consumer Healthcare Approves Unaudited Financial Results for Quarter Ended March 31, 2026
Sanofi Consumer Healthcare India Limited announced that its Board of Directors, at a meeting held on Tuesday, April 28, 2026, considered and approved the Unaudited Financial Results for the quarter ended March 31, 2026.The financial results provide a detailed view of the company's performance across several key metrics.
Financial Performance Highlights
The company’s financial statements show the total income for the quarter ending March 31, 2026, stood at 2,348. Total expenses were reported at 1,441, leading to a profit for the period of 678.The comprehensive financial performance across the specified periods is presented below:
| Particulars | Quarter ended 31.03.2026 (Unaudited) | Quarter ended 31.12.2025 (Unaudited) | Quarter ended 31.03.2025 (Unaudited) | Year ended 31.12.2025 (Audited) |
|---|---|---|---|---|
| 1. Revenue from Operations | 2,292 | 2,510 | 1,726 | 8,784 |
| 2. Other Income | 56 | 46 | 52 | 184 |
| 3. Total Income | 2,348 | 2,556 | 1,778 | 8,968 |
| (a) Cost of Materials Consumed | 402 | 499 | 189 | 1,607 |
| (b) Purchases of stock in trade | 181 | 61 | 335 | 702 |
| (c) Changes in Inventories | (21) | 123 | (136) | (8) |
| (d) Employee benefits expense | 331 | 355 | 296 | 1,288 |
| (e) Finance costs | 5 | 5 | 4 | 20 |
| (f) Depreciation and amortisation expense | 32 | 34 | 20 | 117 |
| (g) Other expenses | 511 | 574 | 402 | 2,105 |
| Total Expenses | 1,441 | 1,651 | 1,110 | 5,831 |
| 5. Profit before exceptional items and tax | 907 | 905 | 668 | 3,137 |
| 7. Profit before tax | 907 | 905 | 668 | 3,203 |
| Current Tax | 241 | 241 | 170 | 820 |
| Deferred Tax | (12) | (1) | (2) | (18) |
| 9. Profit for the period /year | 678 | 665 | 500 | 2,401 |
| 11. Total comprehensive income | 678 | 651 | 500 | 2,387 |
Note: Basic and diluted earnings per share for the quarter ended 31.03.2026 stood at 29.44, compared to 28.87 for the quarter ended 31.12.2025.
Operational and Product Updates
In terms of product performance, the company noted significant shifts in the market dynamics. Sales of products for the quarter ended March 31, 2026, totaled 2,063.The company highlighted that for the quarter ended March 31, 2026, domestic sales grew by 15.5%. Export sales demonstrated robust growth, increasing by 144.4% compared to the quarter ended March 31, 2025, despite the comparison being on a lower base.
The results for the quarter ended March 31, 2025, were not directly comparable to the current period due to the impact of product recall and subsequent relaunches. In 2024, the company had recalled Depura Kids, Allegra Suspension, and Combiflam Suspension as a precaution. The subsequent relaunches occurred during the quarters ended June 2025 (Combiflam Suspension) and September 2025 (Allegra Suspension and Depura Kids).
Employee Benefits Expense
Regarding the employee benefits expense, the company recognized an incremental financial impact of 24 million as past service cost. This increase is due to the change in the definition of wages, leading to an increase in gratuity liability and compensated absences, recorded in the quarter and year ended December 31, 2025.The company also confirmed that the New Labour Codes, notified by the Government of India, are expected to impact employee benefits, and it will continue to evaluate the final Central and State Rules and associated financial implications.
SANOFICONR Stock Price Movement
Today, Sanofi Consumer Healthcare India Limited shares edged higher, settling at ₹4682.5 after gaining 0.90% on the board. The stock saw notable activity, trading on a volume of 7,193 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.